Valproate for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Wang, Yijun ^a,b   Xia, Jun ^c   Helfer, Bartosz ^b   Li, Chunbo ^d   Leucht, Stefan ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NEUROLEPTIC AGENT; PLACEBO; VALPROIC ACID; TRANQUILIZER;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADVERSE OUTCOME; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ASTHENIA; ATAXIA; BLOOD CELL COUNT; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERSALIVATION; INPATIENT MULTIDIMENSIONAL PSYCHIATRIC SCALE; MENTAL HEALTH; MODIFIED OVERT AGGRESSION SCALE; NAUSEA; NEGATIVE SYNDROME; PAIN; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RIGIDITY; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT EMERGENT SYMPTOM SCALE; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA; META ANALYSIS;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; VALPROIC ACID;

EID: 85000398804     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004028.pub4     Document Type: Review

References (195)

1. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wolnlak P, Sommerville W. Effect of divalproex combined with olanzapine or risperidone in participants with acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-92. [2817125]
2. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among participants with schizophrenia receiving olanzapine or risperidone. Psychiatric Services 2004;55(3):290-4. [2817126; MEDLINE: 15001730; Embase 2004111171]
3. Jafari M, Jiang P, Casey DE. Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA. 2004. [2817127; APA Conference Abstracts NR634]
4. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009;34(5):1330-8. [2817129; MEDLINE: 19052541]
5. M02-547 A randomized, double-blind study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia. www.abbvie.com/content/dam/abbviecorp/us/desktop/research/clinical-trials-data-and-information-sharing/synopses/divalproex%20sodium_M02-547.pdf [accessed 08 April 2016]. [4446072]
6. NCT00073164 A study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs an atypical antipsychotic alone in the treatment of schizophrenia. clinicaltrials.gov/ct2/show/NCT00073164 [Date Accessed: 17 November 2003]. [4446073]
7. Citrome L. Schizophrenia and valproate. Psychopharmacology Bulletin. United States of America, 2003; Vol. 37, issue Suppl 2:74-88. [4446075]
8. Citrome L, Daniel D, Wassef A, Tracy K, Wozniak P, Casey D. Antipsychotic monotherapy versus combination treatment with valproate in hospitalized patients with acute schizophrenia: a double-blind, multi-center study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002:NR316. [4446074]
9. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of participants with schizophrenia and hostility. International Clinical Psychopharmacology 2007;22(6):356-62. [2817131; MEDLINE: 17917554]
10. NCT00308360 Risperidone alone vs risperidone plus valproate in the treatment of participants with schizophrenia and hostility. clinicaltrials.gov/ct2/show/NCT00308360 [Date Accessed: 28 March 2006]. [4446076]
11. Nolan K, Shope C, Citrome L, Volavka J. Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study. Psychiatric Quarterly. United States, 2009; Vol. 80, issue 3:167-72. [4446077]
12. Dose M. Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. [2817134]
13. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998;31(4):122-5. [2817133; MEDLINE: 98425840]
14. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia - revisited. British Journal of Psychiatry 1987;150:542-6. [2817136; MEDLINE: 86216395]
15. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for participants with schizophrenia who are stabilized and partially responsive. Journal of Clinical Psychopharmacology 2009;29(3):267-71. [2817138; MEDLINE: 19440081]
16. Guo CR. Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation Linchuang Jingshen Yixue Zazhi 2007;17(3):183-4. [2817140]
17. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic participants. Journal of Clinical Psychopharmacology 1999;19(4):310-5. [2817142; MEDLINE: 99367069]
18. Normann C, Klose P, Hesslinger B, Langosch J, Berger M, Walden J. Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial. PharmacoPsychiatry 1997; Vol. 30:204. [4446078]
19. Walden J, Hesslinger B, Normann C, Langosch J, Berger M. Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998. [4446079]
20. Jia HX, Bian ZY, Zhu H, Jiang T, Wang LF, Liu HB, et al. Effect of sodium valproate on serum concentration and clinical efficacy of clozapine. Linchuang Jingshen Yixue Zazhi 2007;17(5):310-1. [2817144]
21. Jiang CY, Chen JX, He GQ. The effect of adjuvant magnesium valproate sustained - release tablets for schizophrenia with agitation and agitation. Chinese Magazine of Drug Abuse Prevention and Treatment 2009;15(3):175-7. [2817146]
22. Li WS, Yu XD, Cui Y. A comparative study of olanzapine combined with low-dose magnesium valproate sustained-release tablets in the treatment of acute phrase of schizophrenia. Journal of Psychiatry 2008;21(3):178-9. [2817148]
23. Li SS. The effect of aripiprazole combined with magnesium valproate in the treatment of impulse control disorder of schizophrenia Chongqing Medical Journal. 2009;38(7):788, 798. [2817150]
24. Liang HX, Du JY, Wu ZJ. A study of additive effect of sodium-valproate in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2004;14(3):151-2. [2817152]
25. Ma XW. The effect of adjuvant magnesium valproate on schizophrenia China Practical Medicine, 2010;5(12):43-4. [2817153]
26. Liu C. The effect of sodium valproate in participants with schizophrenia. Chinese Journal of Clinical Medicinal Professional Research 2003;70:11, 596-7. [2817155]
27. Liu Z. Sodium valproate in treatment of aggression for psychiatric participants. Chongqing Journal of Medicine 2007;36(6):490-1. [2817157]
28. Lu W, Jin W, Wang H, Ma Y, Tong Z. Comparing study of sodium valproate xr (Depakine) in the supplementary therapy of excitement state in participants with schizophrenia and schizoaffective disorder. Proceedings of the Zhejiang Annual Psychiatry Conference, Yiwu, China. 2005:75-7. [2817159]
29. Lu WM, Jin WD, Shen Y, Ma YC, Tong ZH. Clinical evaluation of sodium valproate xr (Depakine) in adjunctive therapy for participants with excitomania associated with schizophrenia and schizoaffective disorder. Chinese New Drugs Journal 2006;15(15):1291-3. [2817160]
30. Pan ZX, Yin DF, Liu NH. Sodium valproate combined clozapine in the treatment of refractory schizophrenia 34 cases. Herald of Medicine 2010;29(2):203-4. [2817162]
31. Shi YX, Dai TG, Yi PC. A study of olanzapine combined with magnesium valproate sustained-release tablets for the treatment of excitement and agitation in acute phase of schizophrenia. Modern Practical Medicine 2010;22(4):398-9. [2817164]
32. Wang H. Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics. Journal of Clinical Psychosomatic Diseases 2005;11(1):10-1. [2817166; 113903]
33. Wang GP, Xie R, Pei GX, Zhang XJ. The effect of adjuvant magnesium valproate sustained-release tablets in the treatment of schizophrenia. Journal of Clinical Psychiatry 2009;19(4):250-1. [2817168]
34. Wang LJ, Zhang J. A comparative study of sodium valproate combined with other drugs for schizophrenia with impulsive and aggressive behavior. Medical Journal of Chinese People's Health 2010;22(5):548-9. [2817170]
35. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ 3rd, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of Clinical Psychopharmacology 2000;20(3):357-61. [2817172; MEDLINE: 20289870]
36. Xie R, Wang G, Pei G. The effect of adjuvant magnesium valproate sustained-release tablet in the treatment of schizophrenic participants with aggressive behaviours. Journal of Clinical Psychiatry2011;21(3):191-2. [2817174]
37. Yao F, Jiang F. Short-term efficacy of risperidone combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior. Occupation and Health 2010;26(22):2713-4. [2817176]
38. Yin XR, Xie BQ, Jiang L. A double-blind comparative study of sodium valproate in treating of TD. Journal of Clinical Psychological Medicine 2004;14(2):92-3. [2817178; 113903]
39. Zhang SL, Wang CX, Wang LT, Feng YF. The effect of debakin combined with risperidone in the treatment of schizophrenia with psychmotor excitement. Medical Journal of Qilu. 2007;22(3):265-6. [2817180]
40. Alberti GG, Garini R, Marzolini M, Beltz J, Greco MI, Maresca G. Efficacy and tolerability of gabapentin (GBP) and valproate (VPA) as an adjunct in the neuroleptic treatment of acute manic syndromes. Journal of the European College of Neuropsychopharmacology 1999;9:210. [2817182]
41. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disorders 2010;12(4):376-82. [2817184]
42. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, et al. Serum concentrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine or valproate. American Journal of Psychiatry 1994;151(1):123-5. [2817186; MEDLINE: 94091485]
43. Haupt DW, Fahnestock PA, Hessler MJ, Flavin K, Bagley S, Yingling M, et al. Changes in direct measures of adiposity in schizophrenia participants during divalproex augmentation of antipsychotic treatment. Schizophrenia Bulletin 2007;33(2):501. [2817188]
44. Ma XW. The effect of adjuvant magnesium valproate in the treatment of schizophrenia. China Practical Medicine April 2010;5(12):43-4. [2817190]
45. Monfort JC, Mager C, Thorpe D, Ropert R, Ferrey G, Mentre F, et al. Valproate-diazepam combination versus chlorpromazine: a double-blind study in schizophrenic and schizophreniform disorders [Valproate-diazépam versus chlorpromazine: étude en double aveugle dans les troubles schizophréniques et schizophréniformes]. Encephale 1991;17(2):101. [2817192; MEDLINE: 20289870]
46. NCT00183443 Divalproex extended release and placebo, lithium, or quetiapine for mania. clinicaltrials.gov/ct2/show/NCT00183443 [Date Accessed: 13 September 2005]. [2817194]
47. Ping Y, Xinjuan OY, Lin T. A controlled study of sodium valproate and chlorpromazine for schizophrenia. Shanghai Archives of Psychiatry 1994;6(4):208-9. [2817196]
48. Raja M, Azzoni A. Second generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry 2000;22(2):107-14. [2817198; MEDLINE: 20283566]
49. Rifang C, Fenfang Z. The impact of sodium valproate for social function rehabilitation in schizophrenia participants. Modern Rehabilitation 2001;5(9):100. [2817200]
50. Zhu C, Fu R, Yang Y. Sodium valproate and clonazepam for the treatment of agitated symptoms of participants with schizophrenia: a controlled trial. Medical Journal of the Chinese People's Armed Police Forces 2005;16(12):934-5. [2817202; CAJ MEDI0602]
51. Boylan L, Labovitz D. Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia. Neuropyschopharmacology. United States of America, 2004; Vol. 29, issue 3:636. [4446081]
52. Chien C, Jung K, Ross-Townsend A. Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin 1978; Vol. 14, issue 2:20-2. [4446083]
53. Cui LJ, Shen WM. Effects of magnesium valproate treatment on weight and blood insulin levels in patients with schizophrenia. Frontiers of Medicine 2012; Vol. 22:97. [4446085]
54. Ellenor G, Lohr J, Ito M, Dishman B, Gammariello A. The comparative efficacy of divalproex low and high serum level in bipolar disorder and schizophrenia. Psychopharmacology Bulletin 1995; Vol. 31, issue 3:563. [4446087]
55. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatrica Scandinavica 1983;67(3):178-87. [2817204; MEDLINE: 83227217]
56. Gong Y, Guo P. Effects of magnesium valproate on cognitive function in patients with refractory schizophrenia. Chronic Pathematology Journal 2010; Vol. 12, issue 2:107-9. [4446089]
57. Gu P, Wang J, Cao J, Li B-z. A comparative study of quetiapine with sustained-release tablets of magnesium valproate in treatment of old patients with acute phase of schizophrenia. Chinese Journal of Clinical Psychology 2012; Vol. 20, issue 4:520-2. [4446091]
58. Gu Q. Prognostic analysis of magnesium valproate combined with antipsychotics for patients with convalescent schizophrenia. Medical Journal of Chinese People's Health 2014; Vol. 26, issue 18:59, 99. [4446093]
59. Huang WD, Luo HF, Lan L, Li CH, Xu LH, Li ZM. Efficacy of ziprasidone combined with low-dose sodium valproate in the treatment of female refractory schizophrenia. Youjiang Medical Journal 2013, issue 02:159-62. [4446095]
60. Jiang TC, Xiong Y. Efficacy of quetiapine combined with sodium valproate in the treatment of schizophrenia with impulsive and aggression in female patients. World Latest Medicine Information 2014; Vol. 14, issue 32:79-80. [4446097]
61. Jin G. Efficacy of magnesium valproate for schizophrenia with impulsive and aggressive behavior. Chinese Journal of Modern Drug Application 2013, issue 14:160-1. [4446099]
62. Lee MS, Choi BH, Kim SH. Combined use of carbamazepine and valproic acid in negative symptom schizophrenia. 9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands. 1996. [2817206; MEDLINE: 83227217]
63. Li W, Yu X, Cui Y. A comparative study of olanzapine with small-dose sustained-release tablets of magnesium valproate in treatment of acute phase of schizophrenia. Shandong Archives of Psychiatry 2008;21(3):178-9. [4446101]
64. Li DM. Clinical efficacy of ziprasidone combined with valproate in the treatment of refractory schizophrenia. China Medical Engineering 2012, issue 01:92-3. [4446103]
65. Li C, Liu Y, Wang M. The effect of adjuvant magnesium valproate sustained-release tablets combined with risperidone in the treatment of schizophrenia with impulsive aggression. Journal of Practical Medical Techniques. 2013, issue 01:69-71. [4446105]
66. Li J, Chen LS, Chen Wang Y. A comparative study of effect of sodium valproate on cognitive dysfunction in patients with schizophrenia. Journal of Psychiatry 2013, issue 04:292-4. [4446107]
67. Li YM, Sun WB, Yang CQ. A study of low-dose quetiapine combined with magnesium valproate in the treatment of schizophrenia. Medical Information 2014; Vol. 27, issue 24:47-8. [4446109]
68. Li Y. A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia. The Chinese and Foreign Health Abstract 2014, issue 11:53. [4446111]
69. Liang H-X, Du J-Y, Wu Z-J. A study of additive effect of sodium-valproate in the treatment of schizophrenia. Journal of Clinical Psychological Medicine 2004;14(2):92-3. [4446113]
70. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry 1976;129:114-9. [2817208; MEDLINE: 77000897]
71. Linnoila M, Viukari M, Hietala O. Sodium valproate therapy for tardive dyskinesia. International Drug Therapy Newsletter 1976;11(Nov):33-5. [4446115; MEDLINE: 14-01616]
72. Liu Z. Sodium valproate in treatment of aggression of psychiatric participants 2007;36(6):490-1. [4446117]
73. Liu Z, Wang L, Sun Y. Clinical observation of magnesium valproate sustained-release tablets for schizophrenia with excitement. China Journal of Health Psychology 2012; Vol. 20, issue 11:1630-1. [4446119]
74. Liu J. The effect of adjuvant magnesium valproate on schizophrenia with aggressive behavior. Journal of Community Medicine 2012; Vol. 10, issue 14:31-2. [4446121]
75. Liu Z, Song S, Wang L. Effects of magnesium valproate sustained-release tablets combined with risperdal on lipid metabolism in patients with schizophrenia. China Journal of Health Psychology 2013; Vol. 21, issue 11:1631-2. [4446123]
76. Liu Z, Li HJ, Pei SY. Effects of risperidone and magnesium valproate on blood concentration in patients with schizophrenia. China Journal of Health Psychology 2014; Vol. 22, issue 8:1141-3. [4446125]
77. Lv S. Effects of magnesium valproate sustained-release tablets on cognitive function in first-episode schizophrenic patients. China & Foreign Medical Treatment 2014, issue 17:120-1. [4446127]
78. Ma TB. Analysis of effects of valproic acid sodium jointed with ziprasidone in the treatment of refractory schizophrenia. China Modern Medicine 2012, issue 04:73-4. [4446129]
79. Monteleone P, Maj M, Iovino M, Steardo L. Growth hormone response to sodium valproate in chronic schizophrenia. Biological Psychiatry 1986; Vol. 21, issue 7:588-94. [4446131]
80. Monteleone P, Maj M, Ariano M, Iovino M, Fiorenza L, Steardo L. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 1988; Vol. 96, issue 2:223-6. [4446133]
81. Nair N, Lal S, Schwartz G. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. In: Cattabeni FRG editor(s). Long Term Effects of Neuroleptics. Advances in Biochemistry and Psychopharmacology. Vol. 24, New York, USA: Raven Press, 1980:437-41. [4446135]
82. Nasrallah H, Dunner F, McCalley Whitters M, Smith R. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. Journal of Clinical Psychological Medicine. United-States, 1986; Vol. 47, issue 2:56-9. [4446137]
83. NCT00552500 Effects of atypical antipsychotic and valproate combination therapy on glucose and lipid metabolism in schizophrenia. clinicaltrials.gov/ct2/show/NCT00552500 [Date Accessed: 1 November 2007]. [4446139]
84. Peng ZY, Xia CL, Liu XM. A comparative study of clozapine and clozapine unite magnesium valproate in the treatment of patients with treatment-resistant schizophrenia. World Health Digest Medical Periodieal 2012; Vol. 38:164-6. [4446141]
85. Peng H. Effect of magnesium valproate on aggressive behavior in schizophrenia. Chinese Journal of Trauma and Disability Medicine 2013, issue 07:187-8. [4446143]
86. Pu QX, Wu HB, Huang X, Yu GH, Wang DF, Gu ZW, et al. Contrast analysis of olanzapine combined with sodium valproate on refractory schizophrenia. Progress in Modern Biomedicine 2013, issue 18:3503-6. [4446145]
87. Qiu LL, Wang JF. Effect of sodium valproate on risperidone therapy and blood concentration. Medical Journal of Liaoning 2014; Vol. 28, issue 1:9-10. [4446147]
88. Qu CH, Liu XL, Sun XH. A comparative study of valproate combined with olanzapine in the treatment of schizophrenia. Medical Information 2014; Vol. 27, issue 21:602. [4446149]
89. Ruiz-Doblado S, Baena-Baldomero A, Esparrago-Llorca G. Pharmacological augmentation strategies in clozapine-resistant schizophrenia: overcoming the resistance. Psiquiatria Biologica 2010;17(3):96-101. [4446151]
90. Shu Z, Zhou W. Clinical observation of clozapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia. Guide of China Medicine 2014; Vol. 12, issue 2:28-9. [4446153]
91. Su L, Xu Y, Shi S, Dutt A, Bramon E. Effects of chlorpromazine, clozapine and valproate on auditory P300 in schizophrenia: a prospective longitudinal randomized controlled study. Schizophrenia Bulletin 2013; Vol. 39:S51. [4446155]
92. Sun Q, Quo H, Zhang H, Liu Y, Zhu Y, Zhang A. The effects of magnesium valproate sustained release tablets on the cognitive function in treatment-resistant schizophrenic participants. Proceedings of the Shanghai Regional Meeting and CSP Annual Congress; 2007 Sep 20-23; Shanghai. 2007. [2817212]
93. Sun Q-X, Guo H, Liu Y. Effect of magnesium valproate sustained release tablets on cognition function in difficult cure sex schizophrenic. Chinese Journal of Modern Drug Application 2008;2(22):25-7. [4446157]
94. Sun XG. A comparative study of quetiapine combined with haloperidol, sodium valproate and clozapine in the treatment of refractory schizophrenia. Medical Journal of Chinese People's Health 2012; Vol. 24, issue 13:1566-7. [4446159]
95. Suzana S, Olivera Z, Gordana N, Violeta S, Dragoslava G, Vladica S. Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia. European Neuropsychopharmacology 2009; Vol. 19:S532. [4446161]
96. Tang SY, Qin CL, Zhang W, Xiong MQ. Clinical observation of sodium valproate sustained-release tablets on schizophrenia hostile attack. J Medical Forum 2012; Vol. 9:36-7. [4446163]
97. Wang H. Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics. Journal of Clinical Psychosomatic Diseases 2005;11(1):10-1. [4446165]
98. Wang HL. Therapeutic effect of risperidone combined with magnesium valproate in aggressive behaviors of schizophrenics. Chinese Journal of Health Psychology 2006;14(4):441-2. [2817210]
99. Wang G, Xie R, Pei G. A comparative study of quetiapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior. Journal of Psychiatry 2012, issue 01:59-60. [4446167]
100. Wang Y. Efficacy of olanzapine combined with magnesium valproate in the treatment of schizophrenia. Chinese Journal of General Practice 2013, issue 05:730+749. [4446169]
101. Wang ML, Jiang TC. Clinical observation of risperidone combined with sodium valproate in the treatment of schizophrenia with impulse and aggressive behavior. Clinical Rational Drug Use 2013, issue 01:72-3. [4446171]
102. Wang GL, Fu PX, Li XY, Lin JX, Ji QS, Li ZJ. A comparative study of the efficacy of risperidone combined with valproate sodium on the aggressive behavior of the patients with schizophrenia. Chinese Journal of Drug Abuse Prevention and Treatment 2014; Vol. 20, issue 4:200-2. [4446173]
103. Wang ZB. The effect of adjuvant sodium valproate for schizophrenia with behavioral disorders. Medical Journal of Chinese People's Health 2014; Vol. 26, issue 22:57-8. [4446175]
104. Wen J, Li Y, Wang G. Clinical efficacy and safety of quetiapine combined with magnesium valproate in the treatment of schizophrenia with aggressive behavior. Medical Journal of Chinese Civil Administration 2013, issue 11:55-6. [4446177]
105. Wu J, Lin T. Efficacy of magnesium valproate combined with quetiapine in the treatment of refractory schizophrenia. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2013, issue 04:140-1. [4446179]
106. Wu X, Yang Q, Zhang L, Zhou S. A comparative study of olanzapine combined with magnesium valproate sustained-release tablets in the treatment of patients with positive symptoms of schizophrenia Medical Journal of West China 2013, issue 12:1842-4. [4446181]
107. Xiao H. A retrospective study of risperidone combined with magnesium valproate in the treatment of schizophrenia Nei Mongol Journal of Traditional Chinese Medicine 2013, issue 06:30-1. [4446183]
108. Xu HL, Wang Y. The effect of adjuvant sodium valproate on auditory hallucinations in schizophrenia Journal of Clinical Psychological Medicine 2002; Vol. 12, issue 3:157-8. [4446185]
109. Xu LH, Huang WD, Li CH, Ban RY, Luo HF, Li ZM. Ziprasidone combined with low-dose sodium valproate in the treatment and nursing of female refractory schizophrenia Journal of Aerospace Medicine 2013, issue 09:1133-5. [4446187]
110. Xu BF, Lou YM, Cai XH. Effects of magnesium valproate sustained-release tablets combined with clozapine in the treatment of female refractory schizophrenia Chinese Journal of Trauma and Disability Medicine 2014; Vol. 22, issue 6:148-9. [4446189]
111. Zhang S-L, Wang C-X, Wang L-T. Therapeutic efficacy of combination of risperidone with Depakine for schizophrenia. Medical Journal of Qilu 2007;22(3):265-6. [4446191]
112. Zhang DW, Dai J, Xie WF, Chen WT. Sodium valproate combined with EEG as an adjuvant therapy for schizophrenia Medical Journal of Chinese People's Health 2007; Vol. 19, issue 12:1049, 1051. [4446193]
113. Zhang X, Wang XM. Magnesium valproate combined with risperidone in the treatment of schizophrenia with negative symptoms Chinese Journal of Misdiagnostics 2008; Vol. 18, issue 18:4361-2. [4446195]
114. Zhang X, Ye CP, Liu WP. Efficacy of sodium valproate combined with haloperidol in the treatment of early schizophrenia Chinese and Foreign Medical Research 2012; Vol. 23:38-9. [4446197]
115. Zhou YH, Zhong YF, Zeng DZ, Dai LJ. Efficacy of magnesium valproate sustained-release tablets combined with ziprasidone in the treatment of schizophrenia with aggressive behavior The 10th National conference of Psychiatry of Chinese Medical Association 2012:1. [4446199]
116. Zhou LC, Nong YX, Chen QM. Effect and safety comparison of risperidone single therapy or combined valproate on excited restless of schizophrenia Journal of Clinical Psychological Medicine 2013, issue 04:261-2. [4446201]
117. Zhou W, Xie WJ, Hu YZ. Clinical observation of olanzapine combined sustained-release magnesium valproate tablet treating male schizophrenic patients with aggressive behavior Journal of Clinical Psychiatry 2014; Vol. 24, issue 3:194-6. [4446203]
118. Zhu CH, Fu R, Yang Y. A comparative study of sodium valproate combined with clonazepam for schizophrenic agitation Medical Journal of the Chinese People's Armed Police Forces 2005;16(12):934-5. [4446205]
119. Zhu YT, Zeng DF. A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia China Practical Medicine 2014; Vol. 9, issue 13:140-1. [4446207]
120. NCT00167934 Metabolic effects of valproate and antipsychotic therapy. clinicaltrials.gov/ct2/show/NCT00167934 [Date Accessed: 9 September 2005]. [2817214]
121. NCT00306475 Does the addition of divalproex sodium ER to an atypical antipsychotic drug (APD) improve cognition and psychopathology in outpatients with schizophrenia (sch) or schizoaffective disorder (sad)?. clinicaltrials.gov/ct2/show/NCT00306475 [Date Accessed: 22 March 2006]. [2817216]
122. Norrie PD. Valproate augmentation of antipsychotic therapy. International Journal of Neuropsychopharmacology 2000;3 (Suppl 1):S173. [2817218]
123. Wang G. 60 week, randomized, double-blind, placebo-controlled trial of valproate added to risperidone in 200 treatment-naive, first-episode participants with schizophrenia. Stanley Foundation Research Programs 2003. [2817220]
124. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
125. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
126. Andreasen NC. Scale for the assessment of negative symptoms. British Journal of Psychiatry 1989;155:53-8.
127. Baethge C. Long-term treatment of schizoaffective disorder: review and recommendations. Pharmacopsychiatry 2003;36(2):45-56.
128. Bagnall AM, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001945]
129. Bailer M. Chemical properties of antiepileptic drugs (AEDs). Advanced Drug Delivery Reviews 2012;64(10):887-95.
130. Balen RM, Procyshyn RM. Valproic acid for seizure prophylaxis during clozapine therapy: where's the evidence?. International Journal of Psychiatry in Clinical Practice 1999;3(4):249-51.
131. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
132. Besag FMC, Berry D Interactions between antiepileptic and antipsychotic drugs. Drug Safety 2006;29(2):95-118.
133. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
134. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
135. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
136. Carta, MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. Journal of Affective Disorders June 2003;75(1):83-91.
137. Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD000234]
138. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
139. Citrome L, Levine L, Allingham B. Changes in use of valproate and other mood stabilizers for participants with schizophrenia from 1994 to 1998. Psychiatric Services 2000;51(5):634-8.
140. Crowhurst N. Philosophy, care and treatment on the psychiatric intensive care unit: themes, trends and future practice. Journal of Psychiatric and Mental Health Nursing 2002;9(6):689-95.
141. Davey Smith G, Egger M. Meta-analysis: unresolved issues and future developments. BMJ 1998;16:221-5.
142. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. Journal of Clinical Psychopharmacology 2000;20(1):1-17.
143. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
144. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
145. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' participant care behavior. Journal of General Internal Medicine 1992;7:623-9.
146. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD006391.pub2]
147. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
148. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
149. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
150. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2]
151. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. The American Journal of Psychiatry 1998;155(1):12-21.
152. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
153. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002306]
154. Goodman F, Glassman, P, Maglione M, Suttorp M. Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia. Oregon Health & Science University, 2006.
155. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
156. Guy U. ECDEU assessment manual for psychopharmacology. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. Washington DC: National Institute of Mental Health, 1976.
157. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
158. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
159. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
160. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
161. Hiller W, Zerssen D, Mombour W, Wittchen HU. Inpatient Multidimensional Psychiatric Scale. Eine multidimensionale Skala zur systematischen Erfassung des psychopathologischen Befundes (Dt. Version). Manual. Weinheim: Beltz Test GmbH, 1986.
162. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
163. Konstantinos N, Fountoulakis, Siegfried K, Ole A, Pierre B, Ahmed O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience 2012;262(1):1-48.
164. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
165. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
166. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
167. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003834.pub2]
168. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001258.pub2]
169. Mallinckrodt CH, Watkin JG, Molenberghs G, Carroll RJ. Choice of the primary analysis in longitudinal clinical trials. Pharmaceutical Statistics 2004;3:161-9.
170. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
171. Marvaha S, Johnson S. Schizophrenia and employment? A review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
172. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;258:1987-91.
173. National Institute of Mental Health. Clinical Global Impression. In: Guy W, Bonato RR editor(s). Manual for the ECDEU Assessment. 2nd Edition. NIMH, 1970.
174. Guy W. ECDEU Assessment Manual for Psychopharmacology. ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, 1991.
175. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
176. Pajonk FG. Clinical trial design in schizophrenia: implications for clinical decisions. Current Opinion in Psychiatry 2005;18(6):692-99.
177. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Archives of General Psychiatry 2005;62(3):247-53.
178. Pantelis C, Barnes TRE. Drug strategies and treatment-resistant schizophrenia. Australian and New Zealand Journal of Psychiatry 1996;20(1):20-37.
179. Perugi G, Ruffolo G. The empirical basis of the use of antiepileptics in the treatment of bipolar disorder. Clinical Neuropsychiatry 2004;1(3):165-74.
180. Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
181. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
182. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
183. Simpson M, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavia 1970;212:11-9.
184. Sommer IE, Begemann MJH, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients With insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 2012;38(5):1003-11.
185. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000967.pub2]
186. Stahl, SM, Grady, MM A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry 2004;11(3):313-27.
187. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
188. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD000076.pub2]
189. Tranulis C, Mouaffak F, Chouchana L, Stip E, Gourevitch R, Poirier MF, et al. Somatic augmentation strategies in clozapine resistance - what facts?. Clinical Neuropharmacology 2006;29(1):34-44.
190. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-55.
191. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92. [MEDLINE: 10982317]
192. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Drop-out rates in randomised antipsychotic drug trials. Psychopharmacology 2001;155:230-3.
193. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
194. Leucht S, White P, McGrath J, Kissling W. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 2004;65:177-86.
195. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004028.pub3]